

Lisa M Butler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8472984/publications.pdf>

Version: 2024-02-01

134
papers

6,723
citations

66343
42
h-index

71685
76
g-index

144
all docs

144
docs citations

144
times ranked

9930
citing authors

#	ARTICLE	IF	CITATIONS
1	The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11700-11705.	7.1	475
2	Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discovery, 2012, 2, 1134-1149.	9.4	354
3	Androgen Receptor Inhibits Estrogen Receptor- α Activity and Is Prognostic in Breast Cancer. Cancer Research, 2009, 69, 6131-6140.	0.9	329
4	Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Advanced Drug Delivery Reviews, 2020, 159, 245-293.	13.7	316
5	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 2004, 11, 459-476.	3.1	212
6	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 2012, 11, 2756-2761.	2.6	201
7	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 631-640.	7.1	198
8	Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 2012, 131, 652-661.	5.1	169
9	Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nature Reviews Cancer, 2021, 21, 753-766.	28.4	167
10	Maximizing the Therapeutic Potential of HSP90 Inhibitors. Molecular Cancer Research, 2015, 13, 1445-1451.	3.4	161
11	Cancer-associated fibroblasts—“heroes or villains?”. British Journal of Cancer, 2019, 121, 293-302.	6.4	155
12	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	2.5	145
13	Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer. Nature Communications, 2013, 4, 1923.	12.8	125
14	Minireview: The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 2008, 22, 2373-2382.	3.7	121
15	Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 2013, 109, 641-650.	6.4	117
16	Ex vivo culture of human prostate tissue and drug development. Nature Reviews Urology, 2013, 10, 483-487.	3.8	111
17	The diversity and breadth of cancer cell fatty acid metabolism. Cancer & Metabolism, 2021, 9, 2.	5.0	107
18	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. ELife, 2020, 9, .	6.0	104

#	ARTICLE	IF	CITATIONS
19	Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 51-60.	4.1	103
20	Targeting cell cycle and hormone receptor pathways in cancer. <i>Oncogene</i> , 2013, 32, 5481-5491.	5.9	98
21	Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. <i>Endocrine-Related Cancer</i> , 2016, 23, R219-R227.	3.1	95
22	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.9	94
23	A patientâ€derived explant (<sc>PDE</sc>) model of hormoneâ€dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	4.6	94
24	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by <i>Ex Vivo</i> Culture of Human Prostate Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 3562-3570.	7.0	92
25	A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. <i>Oncogene</i> , 2017, 36, 24-34.	5.9	85
26	Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamineâ€Rich Tetratricopeptide Repeat Containing Protein Î±. <i>Cancer Research</i> , 2007, 67, 10087-10096.	0.9	82
27	Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. <i>FASEB Journal</i> , 2007, 21, 2285-2293.	0.5	76
28	The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. <i>Gastroenterology</i> , 2021, 160, 1224-1239.e30.	1.3	76
29	The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. <i>International Journal of Cancer</i> , 2006, 119, 944-954.	5.1	68
30	Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 110, 236-243.	2.5	65
31	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 949-962.	3.4	65
32	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 2328-2341.	7.0	63
33	The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis. <i>Gastroenterology</i> , 2022, 162, 890-906.	1.3	63
34	Periâ€prostatic adipose tissue: the metabolic microenvironment of prostate cancer. <i>BJU International</i> , 2018, 121, 9-21.	2.5	60
35	Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate. <i>Cancer Research</i> , 2005, 65, 8487-8496.	0.9	58
36	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. <i>EMBO Reports</i> , 2020, 21, e50162.	4.5	58

#	ARTICLE	IF	CITATIONS
37	Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Medical and Pediatric Oncology, 2000, 35, 577-581.	1.0	57
38	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 2013, 4, 691-704.	1.8	57
39	An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 2012, 19, 599-613.	3.1	51
40	GSTP1 DNA Methylation and Expression Status Is Indicative of 5-aza-2'-Deoxycytidine Efficacy in Human Prostate Cancer Cells. PLoS ONE, 2011, 6, e25634.	2.5	49
41	Effect of FAK inhibitor VSâ€6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate, 2018, 78, 308-317.	2.3	48
42	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Research, 2021, 81, 1704-1718.	0.9	44
43	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. Cancer Research, 2021, 81, 4981-4993.	0.9	43
44	Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. British Journal of Cancer, 1998, 77, 1454-1459.	6.4	42
45	Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 2012, 357, 60-70.	3.2	42
46	Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 2012, 19, R99-R113.	3.1	40
47	DEREGULATION OF APOPTOSIS IN COLORECTAL CARCINOMA: THEORETICAL AND THERAPEUTIC IMPLICATIONS. Australian and New Zealand Journal of Surgery, 1999, 69, 88-94.	0.2	37
48	Altered Endosome Biogenesis in Prostate Cancer Has Biomarker Potential. Molecular Cancer Research, 2014, 12, 1851-1862.	3.4	37
49	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European Urology Oncology, 2018, 1, 325-337.	5.4	37
50	Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. Oncotarget, 2015, 6, 37919-37929.	1.8	36
51	Molecular pathology and prostate cancer therapeutics: from biology to bedside. Journal of Pathology, 2014, 232, 178-184.	4.5	34
52	Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 2014, 21, L17-L21.	3.1	34
53	A gene signature identified using a mouse model of androgen receptorâ€dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 2012, 131, 662-672.	5.1	33
54	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Reports, 2021, 34, 108585.	6.4	33

#	ARTICLE	IF	CITATIONS
55	Hsp90: Still a viable target in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 211-218.	7.4	32
56	Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. <i>Scientific Reports</i> , 2018, 8, 2090.	3.3	31
57	SGTA: A New Player in the Molecular Co-Chaperone Game. <i>Hormones and Cancer</i> , 2013, 4, 343-357.	4.9	30
58	Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. <i>British Journal of Cancer</i> , 2000, 82, 131-135.	6.4	29
59	GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. <i>Biological Chemistry</i> , 2005, 386, 69-74.	2.5	29
60	Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. <i>British Journal of Cancer</i> , 2018, 118, 713-726.	6.4	28
61	Lipogenic effects of androgen signaling in normal and malignant prostate. <i>Asian Journal of Urology</i> , 2020, 7, 258-270.	1.2	27
62	Ex vivo culture of intact human patient derived pancreatic tumour tissue. <i>Scientific Reports</i> , 2021, 11, 1944.	3.3	27
63	The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2689-2700.	4.1	26
64	Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1470-1486.	3.8	26
65	Maximizing RNA Loading for Gene Silencing Using Porous Silicon Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 22993-23005.	8.0	26
66	eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. <i>Biochemical Journal</i> , 2020, 477, 4367-4381.	3.7	25
67	Bringing androgens up a NOTCH in breast cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T183-T202.	3.1	24
68	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. <i>Endocrine-Related Cancer</i> , 2015, 22, 805-818.	3.1	24
69	A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. <i>Prostate</i> , 2016, 76, 1546-1559.	2.3	23
70	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021, 72, 103625.	6.1	23
71	Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. <i>Cancer Discovery</i> , 2022, 12, 2074-2097.	9.4	22
72	Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. <i>International Journal of Cancer</i> , 2013, 133, 2812-2823.	5.1	21

#	ARTICLE	IF	CITATIONS
73	Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 2695-2708.	3.7	21
74	Remodeling of the Lymphatic Vasculature during Mouse Mammary Gland Morphogenesis Is Mediated via Epithelial-Derived Lymphangiogenic Stimuli. <i>American Journal of Pathology</i> , 2012, 181, 2225-2238.	3.8	20
75	Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. <i>Journal of Molecular Endocrinology</i> , 2012, 49, 57-68.	2.5	19
76	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030478.	6.2	19
77	The inverse relationship between prostate specific antigen (PSA) and obesity. <i>Endocrine-Related Cancer</i> , 2018, 25, 933-941.	3.1	19
78	The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma. <i>Cancer Letters</i> , 1999, 143, 29-35.	7.2	18
79	Prostate cell lines as models for biomarker discovery: Performance of current markers and the search for new biomarkers. <i>Prostate</i> , 2014, 74, 547-560.	2.3	18
80	Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. <i>Histopathology</i> , 2020, 76, 976-987.	2.9	18
81	Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant. <i>Molecular Endocrinology</i> , 2006, 20, 1009-1024.	3.7	17
82	Characterization of the prostate cancer susceptibility gene <i>KLF6</i> in human and mouse prostate cancers. <i>Prostate</i> , 2013, 73, 182-193.	2.3	17
83	Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. <i>Menopause</i> , 2014, 21, 79-88.	2.0	17
84	A feedback loop between the androgen receptor and 6-phosphogluconate dehydrogenase (6PGD) drives prostate cancer growth. <i>ELife</i> , 2021, 10, .	6.0	16
85	High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 44492-44504.	1.8	16
86	Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. <i>Cancer & Metabolism</i> , 2022, 10, 1.	5.0	16
87	Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2011, 342, 20-31.	3.2	15
88	Osteoblast derived-neurotrophin-3 induces cartilage removal proteases and osteoclast-mediated function at injured growth plate in rats. <i>Bone</i> , 2018, 116, 232-247.	2.9	15
89	Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. <i>BMC Biochemistry</i> , 2013, 14, 10.	4.4	14
90	Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry. <i>Scientific Reports</i> , 2019, 9, 15008.	3.3	14

#	ARTICLE	IF	CITATIONS
91	Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cellular and Molecular Life Sciences, 2021, 78, 249-270.	5.4	14
92	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 860-870.	3.9	14
93	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	5.1	13
94	Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. Molecular Cancer Research, 2020, 18, 1500-1511.	3.4	13
95	Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics. Cancers, 2022, 14, 1702.	3.7	13
96	The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1795, 104-109.	7.4	12
97	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,). Tj ETQq1 1 0.784314 rgBT2/Overlock	7.4	12
98	A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 1446-1459.	7.0	12
99	Monounsaturated Fatty Acids: Key Regulators of Cell Viability and Intracellular Signaling in Cancer. Molecular Cancer Research, 2022, 20, 1354-1364.	3.4	12
100	Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice. Scientific Reports, 2016, 6, 28950.	3.3	11
101	Î± mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 2016, 16, 141.	2.6	10
102	Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells. Biointerphases, 2020, 15, 031002.	1.6	10
103	Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. Cancers, 2020, 12, 1385.	3.7	9
104	Patientâ€Derived Prostate Cancer Explants: A Clinically Relevant Model to Assess siRNAâ€Based Nanomedicines. Advanced Healthcare Materials, 2021, 10, 2001594.	7.6	9
105	Precision nanomedicines for prostate cancer. Nanomedicine, 2018, 13, 803-807.	3.3	7
106	Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 2022, 14, 1708.	3.7	6
107	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 2022, 20, 112.	5.5	6
108	Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2009, 2, 619-630.	3.1	5

#	ARTICLE	IF	CITATIONS
109	Sex differences in corneal neovascularization in response to superficial corneal cautery in the rat. PLoS ONE, 2019, 14, e0221566.	2.5	5
110	A Paradigm in Immunocytochemistry, Revealed by Monoclonal Antibodies to Spatially Distinct Epitopes on Syntenin-1. International Journal of Molecular Sciences, 2019, 20, 6035.	4.1	5
111	Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. Methods in Molecular Biology, 2013, 1024, 235-246.	0.9	3
112	Ex vivo Culture and Lentiviral Transduction of Benign Prostatic Hyperplasia (BPH) Samples. Bio-protocol, 2018, 8, .	0.4	3
113	Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer Research Communications, 2022, 2, 706-724.	1.7	3
114	Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 0, , 5.	0.5	2
115	Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and 17 β -4-tibolone. Molecular and Cellular Endocrinology, 2014, 382, 899-908.	3.2	2
116	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear Medicine and Biology, 2021, 93, 37-45.	0.6	2
117	Insights from AR Gene Mutations. , 2009, , 207-240.		2
118	Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Journal of Clinical Oncology, 2019, 37, e16534-e16534.	1.6	2
119	Androgens and the androgen receptor (AR). , 0, , 378-391.		0
120	MP83-08 COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. Journal of Urology, 2017, 197, .	0.4	0
121	Abstract 5367: Medroxyprogesterone acetate impedes 5 α -dihydrotestosterone induced androgen receptor signaling in normal and malignant human breast epithelial cells. , 2010, , .		0
122	Abstract 274: The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. , 2012, , .		0
123	Abstract LB-233: Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling. , 2016, , .		0
124	Abstract 1152: Lipid elongation: an unexplored therapeutic target in prostate cancer. , 2017, , .		0
125	Abstract LB-109: PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. , 2017, , .		0
126	An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 54-54.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Sex hormone-binding globulin (SHBG) as a marker of aggressive prostate cancer. Endocrine Abstracts, 0, , .	0.0	0
128	Lipid elongation in prostate cancer: an androgen regulated process and a novel therapeutic target. Oncology Abstracts, 0, , .	0.0	0
129	Assessing alterations in organelle contacts during prostate cancer development. Oncology Abstracts, 0, , .	0.0	0
130	Abstract 237: DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. , 2020, , .		0
131	Abstract 4761: Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. , 2020, , .		0
132	Abstract 2076: Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. , 2020, , .		0
133	Abstract PO-036: ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress. , 2020, , .		0
134	Abstract 112: Patient derived models reveal impact of the tumor microenvironment on therapeutic response. , 2019, , .		0